ERBB2 and breast cancer: The prognostic role of these biomarkers has been demonstrated in all BC subtypes, particularly in patients with HER-2 positive eBC who did not receive trastuzumab, suggesting a role in the modulation of the inflammatory response of trastuzumab [38].